Cellular response to COVID-19 vaccines in hematologic malignancies patients : a new hope for non-responders?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - 63(2022), 3 vom: 30. März, Seite 743-746 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saad Albichr, Imane [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 07.03.2022 Date Revised 07.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10428194.2021.1998485 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332449610 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332449610 | ||
| 003 | DE-627 | ||
| 005 | 20231225215611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2021.1998485 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332449610 | ||
| 035 | |a (NLM)34706604 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saad Albichr, Imane |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cellular response to COVID-19 vaccines in hematologic malignancies patients |b a new hope for non-responders? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2022 | ||
| 500 | |a Date Revised 07.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cellular immunity | |
| 650 | 4 | |a hematologic malignancies | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a De Greef, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Van Den Neste, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Poiré, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Havelange, Violaine |e verfasserin |4 aut | |
| 700 | 1 | |a Vekemans, Marie-Christiane |e verfasserin |4 aut | |
| 700 | 1 | |a Bailly, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Yombi, Jean-Cyr |e verfasserin |4 aut | |
| 700 | 1 | |a Mzougui, Samy |e verfasserin |4 aut | |
| 700 | 1 | |a Scohy, Anaïs |e verfasserin |4 aut | |
| 700 | 1 | |a Kabamba-Mukadi, Benoît |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 63(2022), 3 vom: 30. März, Seite 743-746 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:3 |g day:30 |g month:03 |g pages:743-746 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2021.1998485 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 3 |b 30 |c 03 |h 743-746 | ||